Nektar starts Phase 3 trials for eczema drug rezpegaldesleukin

July 21, 2026 7:00 AM

Nektar Therapeutics (Nasdaq: NKTR) announced the initiation of two global registrational Phase 3 trials, ZENITH AD-1 and ZENITH AD-2, evaluating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found